Seizert Capital Partners LLC Has $4.40 Million Stock Position in Incyte Corporation $INCY

Seizert Capital Partners LLC raised its position in Incyte Corporation (NASDAQ:INCY) by 27.9% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 64,670 shares of the biopharmaceutical company’s stock after acquiring an additional 14,095 shares during the period. Seizert Capital Partners LLC’s holdings in Incyte were worth $4,404,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of INCY. FNY Investment Advisers LLC acquired a new stake in Incyte in the 2nd quarter valued at $27,000. Banque Transatlantique SA bought a new position in shares of Incyte in the first quarter valued at $26,000. Hilltop National Bank bought a new position in shares of Incyte in the second quarter valued at $37,000. SVB Wealth LLC acquired a new position in shares of Incyte during the first quarter valued at about $39,000. Finally, Geneos Wealth Management Inc. increased its position in shares of Incyte by 350.0% during the first quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 588 shares in the last quarter. 96.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Incyte

In other Incyte news, EVP Lee Heeson sold 3,074 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $94.02, for a total transaction of $289,017.48. Following the completion of the transaction, the executive vice president directly owned 29,241 shares of the company’s stock, valued at approximately $2,749,238.82. This represents a 9.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sheila A. Denton sold 598 shares of the firm’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $101.36, for a total value of $60,613.28. Following the completion of the sale, the executive vice president directly owned 26,569 shares of the company’s stock, valued at $2,693,033.84. This represents a 2.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 4,227 shares of company stock worth $396,327. 17.80% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on INCY shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Incyte in a research report on Wednesday, October 8th. Stifel Nicolaus raised their target price on Incyte from $110.00 to $115.00 and gave the company a “buy” rating in a report on Monday, September 22nd. Piper Sandler lifted their target price on Incyte from $82.00 to $102.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. JPMorgan Chase & Co. lifted their price objective on shares of Incyte from $73.00 to $89.00 and gave the stock a “neutral” rating in a report on Thursday, October 9th. Finally, Royal Bank Of Canada increased their target price on shares of Incyte from $81.00 to $84.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Seven equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Incyte has an average rating of “Hold” and a consensus target price of $92.77.

Incyte Trading Down 0.3%

Shares of Incyte stock opened at $103.89 on Wednesday. The firm has a market cap of $20.40 billion, a PE ratio of 17.40, a P/E/G ratio of 0.70 and a beta of 0.74. Incyte Corporation has a 1 year low of $53.56 and a 1 year high of $109.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.20 and a quick ratio of 2.78. The stock has a fifty day moving average price of $91.06 and a 200-day moving average price of $78.83.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share for the quarter, beating the consensus estimate of $1.65 by $0.61. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.26 billion. Incyte had a net margin of 24.69% and a return on equity of 26.56%. The firm’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.07 earnings per share. Equities research analysts anticipate that Incyte Corporation will post 4.86 EPS for the current year.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.